Statistics from Altmetric.com
Cardiovascular diseases are the major cause of death worldwide and currently affect 36.3% of the US population.w1 The majority of this population comprises patients with acute myocardial infarction (AMI) and chronic ischaemic heart failure. Despite the considerable contribution of percutaneous coronary revascularisation and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) patients, the long term benefits remain unsatisfactory. Moreover, heart transplantation, as a last resort, is available for a very limited patient population.
Cell transplantation emerged initially as a potential therapy to treat heart failure. Cardiomyocytes are generally considered to be post-mitotic, and do not regenerate upon loss or damage. However, recently Bergmann and co-workers were able to demonstrate that 50% of adult cardiomyocytes are exchanged during a normal lifespan,1 which has propelled investigations into the potential use of cardiovascular regenerative therapy. Moreover, recent improvements in preparation techniques of stem cells, the creation of stable stem cell lines (master cell banks), as well as the isolation of omnipotent embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells, underscore the potential of stem cell therapy as a viable new avenue in the treatment regimen of cardiac patients.
The majority of preclinical studies and clinical trials to date have evaluated the efficacy of cell therapy mainly in AMI. Cell therapy in the acute phase of a myocardial infarction (MI) is geared towards prevention of cardiomyocyte apoptosis, promotion of local neoangiogenesis, improving myocardial perfusion, and reduction of the local inflammatory response. These will all result in sustained contractile function and a reduction of adverse post-AMI cardiac remodelling, ultimately decreasing major adverse cardiac events and progression into overt chronic heart failure. Numerous preclinical studies and meta-analyses of randomised controlled clinical trials suggest that stem cell therapy by either intravascular or intramyocardial injection in ischaemic heart disease is safe, feasible …
Contributors All authors have provided substantial contributions on different parts of the manuscript (conception, design, and interpretation of the data, tables and figures) and drafted and revised the manuscript for intellectual concept. Finally, all the authors have approved the final version of the manuscript.
Competing interests In compliance with EBAC/EACCME guidelines, all authors participating in Education in Heart have disclosed potential conflicts of interest that might cause a bias in the article. The authors have no competing interests.
Provenance and peer review Commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.